Publications

August 2024

A new research paper on the use of PrTMS® for the treatment of Autism has been published in the Journal of Personalized Medicine! With 123 subjects included in the study: “No adverse effects developed, and 44% of subjects had ASC scale scores reduced to below diagnostic cutoffs. Importantly, in PrTMS responders, the spectral EEG regression flattened, implying a more balanced E/I ratio. Moreover, with older participants, alpha peak frequency increased, a positive correlate of non-verbal cognition.”

August 2023

Personalized repetitive transcranial magnetic stimulation (PrTMS®) for post-traumatic stress disorder (PTSD) in military combat veterans. Authors: Milan T. Makale, Shaghayegh Abbasi, Chad Nybo, Jason Keifer, Lori Christman, J. Kaci Fairchild, Jerome Yesavage, Kenneth Blum, Mark S. Gold, David Baron, Jean Lud Cadet, Igor Elman, Catherine A. Dennen, Kevin T. Murphy.

May 2023

PeakLogic®, Inc. was welcomed back to the Clinical TMS Society’s Annual Meeting in Colorado Springs, Colorado during May of 2023 to present a poster titled ‘A Retrospective Review of the Effects of PrTMS® on Sleep Improvement Scores.’ This study showcases beneficial improvement of sleep quality, duration, interruptions, and how these factors play into the quality of life.

January 2023

PeakLogic®, Inc has created this retrospective review to showcase how patients report they are feeling before, during, and after a course of PrTMS® therapy. Results are based on neurocognitive survey scores administered regularly throughout each patient’s treatment course. *Please see the publication for detail and disclaimed information.

July 2022

The University of Hawaii Department of Psychiatry has released a presentation on PrTMS^® titled ‘Personalized rTMS (PrTMS^®) guided by qEEG provides improved outcome in a patient suffering from concussion, depression, and anxiety following a surfing accident.

June 2022

PeakLogic^®, Inc. was welcomed back to the Clinical TMS Society’s Annual Meeting in Chicago, Illinois during June of 2022 to present a poster titled ‘A Retrospective Review of Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS^®) for patients with a history of concussion.

June 2021

PeakLogic^®, Inc. was accepted by the Clinical TMS Society to present at the annual meeting in West Palm Beach, Florida on June 10-12, 2021. The presentation included a retrospective review of the promising results of their innovative therapy, PrTMS^® on patients with Post-Traumatic Stress Disorder (PTSD).

Disclosures

Individual results cannot be guaranteed and may vary due to numerous factors. The effectiveness of PrTMS treatment is subject to each patient's unique circumstances. Our PrTMS therapy employs specific FDA-cleared third-party medical equipment, authorized for addressing drug-resistant depression in cases where standard treatment approaches have proven ineffective. Our innovative tailored protocols are currently under investigation and are utilized as tools to aid healthcare professionals in managing various conditions.

Administration of these protocols is exclusively within the domain of licensed physicians or qualified medical practitioners. It's important to note that Genesis Behavior Center, Inc. PrTMS by Genesis does not assert its ability to provide a cure for any medical condition, neurocognitive disorder, or disease. The trademarks PrTMs, PrTMS powered by PeakLogic, the PrTMS logo, the PeakLogic logo, and "the peak" are all officially registered trademarks held by PeakLogic, Inc.